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Abstract
Since the early 2000s, evidence has accumulated for a significant differential effect of first-
line antiretroviral therapy (ART) regimens on human immunodeficiency virus (HIV) treat-
ment outcomes, such as CD4 response and viral load suppression. This finding was replicated
in our data from the Harvard President’s Emergency Plan for AIDS Relief (PEPFAR) pro-
gram in Nigeria. Investigators were interested in finding the source of these differences, i.e.,
understanding the mechanisms through which one regimen outperforms another, particularly
via adherence. This amounts to a mediation question with adherence playing the role of
mediator. Existing mediation analysis results, however, have relied on an assumption of no
exposure-induced confounding of the intermediate variable, and generally require an assump-
tion of no unmeasured confounding for nonparametric identification. Both assumptions are
violated by the presence of drug toxicity. In this paper, we relax these assumptions and show
that certain path-specific effects remain identified under weaker conditions. We focus on the
path-specific effect solely mediated by adherence and not by toxicity and propose a suite of
estimators for this effect, including a semiparametric-efficient, multiply-robust estimator. We
illustrate with simulations and present results from a study applying the methodology to the
Harvard PEPFAR data. Supplementary materials are available online.
Keywords: Human immunodeficiency virus, Mediation, Nonparametric identification, Unob-
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1. INTRODUCTION
The President’s Emergency Plan for AIDS Relief (PEPFAR) has been a highly successful pro-
gram that has saved millions of lives worldwide since its inception in 2003. The Harvard School
of Public Health was awarded one of the PEPFAR grants, receiving a total of $362 million for
work in Nigeria, Botswana, and Tanzania. The program has furnished these countries with in-
valuable medical infrastructure and provided AIDS care services in Nigeria for over 160,000
people and treatment to approximately 105,000 of those patients.
Our data set consists of previously antiretroviral therapy (ART)-naïve, human immunodefi-
ciency virus (HIV)-1 infected, adult patients enrolled in the Harvard PEPFAR/AIDS Prevention
Initiative in Nigeria (APIN) program between June 2004 and November 2010 who started ART
in the program and were followed for at least 1 year after initiating ART. Upon entry into the
Harvard/APIN PEPFAR HIV care program, all patients completed informed consent; all consent
forms were approved by the institutional review boards at Harvard, APIN and all the correspond-
ing Harvard/APIN PEPFAR HIV care and treatment sites. Patients not on one of 6 standard
first-line regimens at baseline or seen at two of the hospitals without reliable viral load data were
excluded from the data set. The analysis in this paper consists of only the complete cases, and
results are given for all regimens but d4T+3TC+EFV (see Table 1 note for full drug names), due
to the small sample of patients on this regimen as a consequence of it having been dropped mid-
way through the program. (d4T+3TC+NVP was also dropped, but had a large enough sample to
provide for stable inference.)
The significant funding support for AIDS treatment in resource-limited settings provided
by PEPFAR and other international donor organizations relied on clinical trial data generated in
resource rich settings. In order to maximize the benefit of providing ART to the largest number
of patients, well-established drug regimens that were less costly were recommended and sup-
ported by the program. Studies dating back to the early 2000s have demonstrated evidence that
these first-line regimens were not equally effective (Tang et al., 2012), and indeed, in the Harvard
PEPFAR data, we have observed a significant differential effect of first-line ART regimens on
virologic failure and, to a lesser extent, CD4 count. Since these were first-line regimens in use in
most resource-limited settings, this difference could have widespread implications to the success
2
http://biostats.bepress.com/harvardbiostat/paper186
Table 1: Treatment regimen coding and their estimated average causal effects on risk of virologic
failure (VF) and CD4 count
Patients on RR of log-RR of Mean diff. in
Code ART regimen regimen VF (s.e.) VF (s.e.) CD4 count
1 TDF + 3TC/FTC + EFV 1448 (14.6%) 0.65 (0.014) -0.44 (0.12) 6.9 (7.4)
2 d4T + 3TC + NVP 854 (8.6%) 0.75 (0.017) -0.29 (0.13) -9.7 (6.8)
3 AZT + 3TC + EFV 1003 (10.1%) 0.78 (0.018) -0.25 (0.14) 10.7 (8.7)
4 AZT + 3TC + NVP 4707 (47.4%) 0.82 (0.011) -0.21 (0.078) 17.8 (4.9)
5 TDF + 3TC/FTC + NVP 1919 (19.3%) - - -
NOTE: 3TC=lamivudine, AZT=zidovudine, d4T=stavudine, EFV=efavirenz,
FTC=emtricitabine, NVP=nevirapine, TDF=tenofovir. Effects on risk of virologic failure
are expressed on the risk ratio (RR) and log-risk ratio scale relative to treatment 5 and were
estimated using inverse-probability weighted estimators. Effects on CD4 count are expressed
on the mean difference scale relative to treatment 5 and were estimated using doubly-robust
estimators. All effects adjusted for the confounders listed in Section 2.
of ART programs. These regimens and each of their corresponding total effects on virologic
failure and CD4 count relative to a common reference treatment are reported in Table 1. The
effects on virologic failure are reported as marginal and log-marginal risk ratios, and the effects
on CD4 count and log CD4 count are reported on the mean-difference scale. Treatments were
coded from strongest estimated effect on virologic failure to weakest, and the weakest treatment
(TDF+3TC/FTC+NVP) was chosen as the reference for the purposes of the effects in Table 1.
These effects are contrasts in the population between the risk of virologic failure had one in-
tervened to assign everyone to a comparison-level treatment (1, 2, 3, or 4) and that if one had
intervened to assign everyone to baseline treatment 5. The total effects of these regimens, how-
ever, do not quite tell the whole story. Investigators were interested in finding the source of these
differences, i.e., understanding the mechanisms through which one regimen outperforms another.
Mediation analysis serves to better explain these mechanisms that drive the differences in effects.
This type of analysis has the potential to help target interventions to improve the performance of
the less-robust regimens.
The total effect can be considered as a combination of effects, possibly in conflicting di-
rections, through different pathways from the exposure to the outcome. Therefore, a weak total
effect could be due to a combination of even weaker path-specific effects or several stronger
3
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path-specific effects canceling one another out. One such path-specific effect could work strictly
through biological pathways, in which case this population would benefit most from switch-
ing to a more favorable drug regimen. Alternatively, biological factors might play a compara-
tively smaller role relative to the effect of the treatment through nonbiological pathways, such as
through adherence (Shpitser, 2013). We suspect a lack of adherence to treatment to be a driving
mechanism of the observed differential effects, in which case it would be worth considering how
to improve this mediating factor.
Adherence is widely accepted as a key factor for sustained viral suppression and is consid-
ered a prerequisite for maintenance on a prescribed drug regimen and optimal patient outcomes.
However, the extent to which adherence to a given choice of first-line ART contributes to vi-
rologic failure (defined by the World Health Organization [WHO] as repeat viral load > 1000
copies/mL after 6 months of ART duration) is complex and still poorly understood and is a
pressing mediation question in HIV research (Bangsberg et al., 2000). Understanding this issue
is particularly important in resource-limited settings, where ART regimen options are few, and
adherence to lifelong multi-drug daily dosing is challenging, but necessary. In such settings,
quantifying to what degree differential rates of virologic failure are due to differences in adher-
ence rates between therapies would inform the extent to which failure rates could be reduced by
programs that improve adherence rates for certain ARTs, rather than changing the ART regimens
themselves. Such adherence interventions have been very successful in the treatment of tubercu-
losis (China Tuberculosis Control Collaboration, 1996; Fujiwara et al., 1997; Suárez et al., 2001)
and are considered similarly important in the treatment of HIV (Mills et al., 2006; Vranceanu
et al., 2008; Pop-Eleches et al., 2011).
Remark. Technically, the WHO also requires demonstration of adherence in their definition of
virologic failure, which we avoid using in this paper since we cannot study the role of adherence
as a mediator when it is part of the definition of the outcome.
Among other potential mechanisms, the effect of treatment on virologic failure and CD4
count may be mediated by adherence, drug toxicity, or both. This study investigates the extent to
which adherence, and not drug toxicity, mediates the effect, using the Harvard PEPFAR data set.
That is, we focus on the role of adherence when it is differentially affected by the ways the drugs
are obtained and taken, rather than by different levels of toxic side effects. The effect mediated by
4
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nonadherence due to toxicity is unlikely to be appreciable, since toxicity in Nigeria is typically
clinically recognizable and actionable. The magnitude of the roles of other drug-specific predic-
tors of nonadherence, on the other hand, are less understood. These predictors also potentially
point to lower-hanging fruit for development of adherence-promoting interventions. In mediation
analysis terminology, we aim to estimate the effects of treatment assignment on virologic fail-
ure and CD4 count that are indirect with respect to adherence but direct with respect to toxicity.
The definition, identification, and estimation of direct and indirect effects have received much
attention in recent causal inference literature (Robins and Greenland, 1992; Robins, 1999, 2003;
Pearl, 2001; Avin et al., 2005; Taylor et al., 2005; Petersen et al., 2006; Ten Have et al., 2007;
Goetgeluk et al., 2008; van der Laan and Petersen, 2008; VanderWeele, 2009, 2011; VanderWeele
and Vansteelandt, 2009, 2010; Imai et al., 2010a,b; Tchetgen Tchetgen, 2011; Tchetgen Tchetgen
and Shpitser, 2014, 2012; Tchetgen Tchetgen, 2013).
The particular effect we are interested in can be classified as a path-specific effect (Pearl,
2001) – a class of estimands which can represent effects along any given causal pathway or
collection of causal pathways. We consider the effect along the path from the provision of ART to
virologic failure (or CD4 count) that goes through adherence, but not through toxicity. This effect
is a measure of the change in risk of virologic failure (or mean CD4 count) were one to intervene
on the mechanism by which the choice of treatment regimen directly, i.e., not through toxicity,
affects adherence. For instance, if the difference in the effectiveness of ART through adherence
were due to some regimens of ART having certain meal restrictions, posing a greater risk of
patients missing dosages due to issues with food insecurity (Eldred et al., 1998; Gifford et al.,
1998; Roberts, 2000), this effect would reflect the change in mean outcome if we were to modify
the pills such that they can be taken without any meal restrictions. We emphasize our focus on
the pathway through adherence, which does not involve toxicity, to learn about other possible
mediating mechanisms that may be as important as toxicity, but are currently underappreciated.
The presence of an effect through this pathway calls for closer investigation of these possible
mechanisms, such as number of pills taken per dosage or the requirement that they be taken
with meals. The absence indicates that differential effects through other pathways are driving the
observed differences in effects among the treatment assignments. In particular, the efficacies of
the drugs themselves may, in fact, differ, i.e., they may have a differential direct effect on the
5
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outcome with respect to adherence, or they may have a differential effect on adherence due to
their differing levels of toxicity.
Pearl (2001) defines path-specific effects, and Avin et al. (2005) provide general necessary
and sufficient conditions for their identification for a single exposure and outcome, while Shpitser
(2013) generalizes these definitions and conditions to settings with multiple exposures, multiple
outcomes, and possible hidden variables. Our path-specific effect described above satisfies these
identifying conditions, however an estimation strategy for its identifying functional does not yet
exist. In this paper, we develop a suite of estimators (including a multiply-robust, semiparametric-
efficient estimator) for the effect. The HIV case study detailed in this paper also functions as a
guide for the application of this new method to analogous mediation settings where there is
confounding that is affected by the exposure.
2. NOTATION & DEFINITIONS
To formalize our discussion, we begin by defining variables and counterfactuals. We will be con-
sidering pairwise comparisons of first-line ARTs prescribed to most HIV patients in Nigeria. Let
E be an indicator of exposure to one of two such regimens of ART (coding given in Table 1).
For notational simplicity, let e′ denote the “reference level" treatment and e denote the “compar-
ison level" treatment. Let C1 be a bivariate vector of an indicator of any lab toxicities (alanine
transaminase ≥120 UI/L, Creatinine ≥260 mmol/L, Hemoglobin ≤8 g/dL) observed six months
after treatment initiation and an indicator that the patient’s average percent adherence during the
same six months, i.e., the total number of days that the patient had their drug supply divided
by the number of days in the six month period, was no less than 95%. Let M be an indicator
that the patient’s average percent adherence during the subsequent six months was no less than
95%. Let Y be an indicator of whether the patient experienced virologic failure at the end of
the year (based on viral load measurements at twelve and eighteen months for confirmation), or
alternatively CD4 count at twelve months. Let C0 be a vector of baseline confounders of the
causal relationships between E, M , and Y not affected by exposure, viz. sex, age, marital status,
WHO stage, hepatitis C virus, hepatitis B virus, CD4 count, and viral load. Throughout, we will
assume that we observe i.i.d. sampling of O = (C0, E,C1,M, Y ).
We now consider counterfactuals under possible interventions on the variables (Rubin, 1974,
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C0 E C1 M Y
Figure 1: A causal graph with unobserved confounders that allows for identification of thePEMY -
specific effect
1978). Let Y (e∗) denote a patient’s virologic suppression status or CD4 count if assigned, pos-
sibly contrary to fact, to the regimen of ART e∗. In the context of mediation, there will also
be counterfactuals for intermediate variables. We define C1(e∗), M(c1, e∗) and Y (m, e∗) simi-
larly, and adopt the standard set of consistency assumptions (Robins, 1986) that if E = e∗, then
C1(e
∗) = C1 w.p.1, if E = e∗ and C1 = c1, then M(c1, e∗) = M w.p.1, if E = e∗ and M = m,
then Y (m, e∗) = Y w.p.1, and ifE = e∗, then Y (e∗) = Y w.p.1. Additionally, we adopt the stan-
dard set of positivity assumptions (Robins, 1986) that fM |C1,E,C0(m|C1, E,C0) > 0 w.p.1 for
each m ∈ supp(M), fC1|E,C0(c1|E,C0) > 0 w.p.1 for each c1 ∈ supp(C1), fE|C0(e∗|C0) > 0
w.p.1 for each e∗ ∈ {e′, e}.
To define the path-specific effect along the path E →M → Y , which we denote PEMY , we
begin by discussing the graph in Figure 1. This is a complete graph of all observed variables in the
sense that it includes all possible directed arrows that follow the natural temporal ordering. That
is, any variable may directly affect any other variable succeeding it under this graph. The graph
departs from the standard mediation graph (Baron and Kenny, 1986) in two important ways.
The first is with the presence of C1, which allows confounders of the effect of the mediator
on the outcome to be affected by the exposure. In our HIV context, C1 contains toxicity, which
is clearly affected by the treatment assignment and may confound the effect of adherence on
virologic failure. One way in which it might do this is on a biological level, toxicity might have
an interactive effect with the drugs on the outcome, allowed for by the presence of the directed
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arrow from C1 to Y in conjunction with the directed arrow from E to Y . Thus, toxicity is a
common cause of the outcome and adherence and, therefore, a confounder. Such a confounder
is known as a recanting witness, due to its role in telling two conflicting “stories" about how E
affects Y by being involved in two different pathway from E to Y – one involving M and the
other not. Avin et al. (2005) showed the natural (or pure) direct and indirect effects (NDE and
NIE, both highly popular in the mediation literature) (Robins and Greenland, 1992; Pearl, 2001)
to be unidentified in the presence of a recanting witness.
The second way the graph in Figure 1 departs from the standard mediation graph is by the
presence of the gray bidirected edges between C0, C1, and Y , each of which represents unob-
served common causes between the two nodes to which it points. In the HIV application, these
bidirected edges allow for the possibility of underlying biological factors which may be unob-
served common causes of toxicity, the outcome, and biological baseline measurements such as
viral load. The presence of these bidirected edges induces confounding of the effect of adherence
on the outcome via toxicity, even if the arrow directed fromC1 to Y is absent. Since early adher-
ence (during the first six months) may confound the effect of adherence at a later stage (during the
subsequent six months) on the outcome, early adherence must be included in C1. Thus, PEMY
involves only later adherence, and neither toxicity nor early-stage adherence.
As described above, we wish to quantify the mediating role of adherence along PEMY in
Figure 1 which does not involve toxicity. Effects along such arbitrary (bundles of) causal path-
ways are known as path-specific effects (Pearl, 2000; Avin et al., 2005; Shpitser, 2013) and it
is possible to define them inductively, which results in a quantity that is a function of a nested
counterfactual (Shpitser, 2013). A general definition for the static-treatment and single-outcome
case is given by Pearl (2000) and Avin et al. (2005). Defining
β0 ≡ E[Y (M(e,C1(e′)),C1(e′), e′)]
δ0 ≡ E[Y (M(e′,C1(e′)),C1(e′), e′)],
the PEMY -specific effect, with respect to the comparison treatment value e and the baseline
treatment value e′ on the mean difference scale, is given by β0 − δ0. δ0 gives the mean outcome
had everyone been assigned to the reference treatment regimen. β0 gives the mean outcome had
everyone been assigned to the reference treatment regimen, and adhered as they would have based
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on the toxicity they experienced from this regimen, but otherwise as if they had been assigned
to the comparison treatment. This is the PEMY -specific effect since it captures the impact of
changing M(e′) to M(e,C1(e′)), which in turn would lead to an effect on Y only if M affects Y
directly when all patients are assigned to e′.
3. IDENTIFICATION
Before introducing our identification result, we must first introduce a model that relaxes the as-
sumption of independent errors of the Markovian model (Pearl, 2000) in a natural way. We
will associate this model with the graph in Figure 1. This model consists of a set of equa-
tions, one for each variable in the graph. With each random variable on the graph is associ-
ated a distinct, arbitrary function, denoted g, and a distinct random disturbance, denoted ε, each
with a subscript corresponding to its respective random variable. A component in a graph con-
nected by bidirected edges (i.e., connected when ignoring directed edges) is known as a district
(Richardson, 2009) or c-component (Tian and Pearl, 2002). The sets of random disturbances
corresponding to each district are assumed to be mutually independent of one another. That
is, {εC0 , εC1 , εY }, εE , and εM are mutually independent; εC0 , εC1 , and εY , however, are not.
Each variable is generated by its corresponding function, which depends only on all variables
that directly affect it (i.e., its parents on the graph), and its corresponding random disturbance, as
follows: C0 = gC0(εC0), E = gE(C0, εE), C1 = gC1(C0, E, εC1), M = gM(C0, E,C1, εM),
Y = gY (C0, E,C1,M, εY ).
Just as the Markovian model, the model we introduce is especially useful for making coun-
terfactual independence assumptions explicit. Take for instance the statement {Y (m, e′),C1(
e′)}⊥⊥M(c1, e)|C0. To see whether this statement holds in the context of the graph in Figure
1, observe what occurs when we intervene on the mechanism in one case to force the expo-
sure to be the comparison level, e, and set C1 to an arbitrary value c1: C0 = gC0(εC0), E = e,
C1 = c1,M(c1, e) = gM(C0, e, c1, εM), Y (c1, e) = gY (C0, e, c1,M(c1, e), εY ); and in another
case to force the exposure to be the reference level, e′, and set M to an arbitrary value m: C0 =
gC0(εC0), E = e
′, C1(e′) = gC1(C0, e
′, εC1), M = m, Y (m, e
′) = gY (C0, e′,C1(e′),m, εY ).
Note that the only sources of stochasticity in M(c1, e) are C0 and εM , and the only sources of
stochasticity in {Y (m, e′),C1(e′)} are C0, εC1 , and εY . Hence the only source of dependence
9
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between the two isC0 since εM⊥⊥{εC1 , εY }, and they are independent conditional onC0. We are
now prepared to present our identification result, whose proof is provided in the supplementary
materials.
Theorem 1. Suppose the data-generating mechanism from which the observed data O are sam-
pled follows the relaxation of the Markovian model that we introduce above, represented by the
graph in Figure 1. Then β0 is identified under this model by the following functional of FO:
β0 =
∫∫∫
m,c1,c0
E(Y |m, c1, e′, c0)dF (m|c1, e, c0)dF (c1|e′, c0)dF (c0). (1)
Remark. The following conditions are sufficient for the same identification result, and are strictly
weaker than those implied by our model: for all m, c1, e, and e′, {Y (m, e′),C1(e′)}⊥⊥E|C0,
Y (m)⊥⊥M |C1, E,C0, M(c1, e)⊥⊥{C1, E}|C0, {Y (m, e′),C1(e′)}⊥⊥M(c1, e)|C0.
Theorem 1, in conjunction with the standard g-formula result δ0 =
∫
c0
E(Y |e′, c0)dF (c0)
(Robins, 1986), which holds under the assumption encoded on the diagram that Y (e′)⊥⊥E|C0,
identifies the PEMY -specific effect, β0 − δ0.
4. PATH-SPECIFIC INFERENCE
Thus far, we have only considered a nonparametric modelMnonpar for the observed data, mak-
ing our identifying functional of the PEMY -specific effect valid under any possible correct model
for the data. Unfortunately, we will seldom have the luxury to continue usingMnonpar through
the estimation stage; because inference inMnonpar is rarely practical in situations with numer-
ous or continuous confounders (C0,C1) (Robins et al., 1997), we will often be forced to posit
parametric models. Which models we are to fit depend on how we choose to estimate (1). We
now consider four estimators and the corresponding models needed to compute them. Note that,
while these estimators are in fact asymptotically equivalent under a nonparametric model, they
will have different asymptotic properties under parametric and semiparametric models (Tchet-
gen Tchetgen and Shpitser, 2012).
10
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4.1 Maximum Likelihood Estimation
We first discuss the maximum likelihood estimator (MLE) for β0. By considering the identifying
functional (1) as four nested expectations, it is clear that we can fit three appropriate regression
models with parameters γ1, γ2, and γ3 using maximum likelihood, and plug the predicted means
under these models into the functional; the outermost mean can then be estimated empirically. If
the conditional mean of Y is taken to be linear in M and C1, and the conditional mean of M is
taken as linear in C1, then mean models can be fit for Y , M , and C1. Thus, the MLE is
βˆmle ≡ Pn
{
Eˆ(Eˆ(Eˆ(Y |M,C1, e′,C0; γˆ1)|C1, e,C0; γˆ2)|e′,C0; γˆ3)
}
,
where Pn denotes the empirical mean.
Define γ ≡ (γ1,γ2,γ3), g(γ) ≡ Eˆ(Eˆ(Eˆ(Y |M,C1, e′,C0;γ1)|C1, e,C0;γ2)|e′,C0;γ3),
Dγ ≡ E[∇γg(γ)], and U(γ) and I(γ) to be the vector of score equations and block-diagonal
matrix of expected informations, respectively, for γ. Let γ0 be the true value of γ. Then βˆmle is
asymptotically normal with asymptotic variance equal to E[(g(γ0) + DTγ0I(γ0)U(γ0) − β0)2],
which can be estimated empirically, substituting γˆ and βˆmle for γ0 and β0. The MLE is asymp-
totically efficient when the three regression models are correctly specified, hence this is the min-
imum variance achievable by regular, asymptotically linear estimators under the choice of model
Mpar of O. βˆmle will be consistent only under correct specification of the three models.
4.2 Multiply-Robust Estimation
The multiply-robust (MR) estimator, βˆmr, comes from an estimating equation involving the effi-
cient influence function of β0 in the modelMnonpar placing no restriction on the observed data
likelihood apart from the positivity assumptions given above. A derivation of this influence func-
tion is given in the supplementary materials. In order to express the estimator more succinctly,
we introduce additional notation: B(m, c1, e′, c0) ≡ E(Y |m, c1, e′, c0), B′(c1, e′, e, c0) ≡ E{
E(Y |M, c1, e′, c0)|c1, e, c0}, B′′(e′, e, c0) ≡ E[E{E(Y |M,C1, e′, c0)|C1, e, c0}|e′, c0], M ratio
≡ f(M |C1, e,C0)/f(M |C1, e′,C0), and Cratio1 ≡ f(C1|e,C0)/f(C1|e′,C0). The estimator is
11
Hosted by The Berkeley Electronic Press
then
βˆmr =Pn
{
1e′(E)
fˆ(e′|C0)
Mˆ ratio
{
Y − Bˆ(M,C1, e′,C0)
}
+
1e(E)
fˆ(e|C0)
(Cˆratio1 )
−1
{
Bˆ(M,C1, e
′,C0)− Bˆ′(C1, e′, e,C0)
}
+
1e′(E)
fˆ(e′|C0)
{
Bˆ′(C1, e′, e,C0)− Bˆ′′(e′, e,C0)
}
+ Bˆ′′(e′, e,C0)
}
,
where 1e∗(·) is the indicator function, Bˆ′(C1, e′, e,C0) = Eˆ{Bˆ(M,C1, e′,C0)|C1, e,C0}, and
Bˆ′′(e′, e,C0) = Eˆ[Eˆ{Bˆ(M,C1, e′,C0)|C1, e,C0}|e′,C0].
Note that the estimator is only a function of estimates of fM |C1,E,C0 and fC1|E,C0 through
the ratios M ratio and Cratio1 and mean functions B
′(C1, e′, e,C0) and B′′(e′, e,C0). When the
mean of Y is linear inM , thenB′(C1, e′, e,C0) only depends on the distribution ofM through its
conditional mean, E(M |C1, e,C0). Similarly, if in addition the means of Y andM are both linear
in C1, then B′′(e′, e,C0) only depends on the distribution of C1 through its conditional mean,
E(C1|e′,C0). We denote θM ≡ {B′(C1, e′, e,C0),M ratio} and θC1 ≡ {B′′(e′, e,C0), Cratio1 }.
B, θM , θC1 , and fE|C0 are estimated using low dimensional parametric working mod-
els, BW , θWM = {EW [BW (M,C1, e′,C0)|C1, e,C0],M ratio;W}, θWC1 = {EW [B′W (C1, e, c0)|
e′,C0], Cratio:W1 }, and fWE|C0 , via standard maximum likelihood. Note that we are able to avoid
estimating the densities for C1 and M by instead estimating their mean functions and density
ratios directly. Mean functions can be estimated with standard regression techniques, and density
ratios can be estimated using propensity score models since by Bayes’ theorem,
f(C1|e,C0)
f(C1|e′,C0) =
f(e|C1,C0)
f(e′|C1,C0) ×
f(e′|C0)
f(e|C0)
and
f(M |e,C1,C0)
f(M |e′,C1,C0) =
f(e|M,C1,C0)
f(e′|M,C1,C0) ×
f(e′|C1,C0)
f(e|C1,C0) .
An attractive property of the multiply-robust estimator is its robustness to multiple types of
potential model misspecification. Let Bˆ, θˆM, θˆC1 , and fˆE|C0 denote estimators ofB
W , θWM , θ
W
C1
,
and fWE|C0 consistent under correct specification. The mean functions in θM and θC1 require
correct specification of the functions of M and C1 based on the working models for Y and
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{M,Y }, respectively, so that θWM and θWC1 can be correctly specified regardless of whetherBW is,
and θWC1 can be correctly specified regardless of whether θ
W
M is. The multiply-robust estimator is
consistent and asymptotically normal (under standard regularity conditions) provided that one of
the following holds: (a) {θM , fE|C0} ∈ {θWM , fWE|C0}, (b) {B,θC1 , fE|C0} ∈ {BW ,θWC1 , fWE|C0},
(c) {B,θC1 ,θM} ∈ {BW ,θWC1 ,θWM }. That is, βˆmr offers three distinct opportunities to obtain
valid inference about the path-specific effect. By contrast, βˆmle will be consistent only if a slightly
weaker form of (c) holds, where M ratio;W and Cratio;W1 need not be correctly specified.
For inference on βˆmr, we recommend the nonparametric bootstrap (Efron, 1979) or similar
alternative resampling methods such as the wild bootstrap (Mammen, 1993) for nonparametric
variance estimation. Due to its reliance on inverse-propensity-score weights, this estimator may
suffer from instability in settings where the set of positivity assumptions is nearly violated (Kang
and Schafer, 2007). A useful stabilization technique is to simply replace any propensity score
fˆE|X with fˆ
†
E|X, where X is some vector of covariates and logitfˆE|X(e|X) = logitfˆE|X(e|X)
− log(1 − Pn(1e(E))) + log(Pn[1e(E)fˆE|X(e′|X)/fˆE|X(e|X)]), which ensures the weights are
bounded as discussed in Tchetgen Tchetgen and Shpitser (2012). An additional stabilization
technique is given in the supplementary materials.
4.3 Other Estimators
We consider two additional estimators, both based on alternative representations of (1) as shown
in the supplementary materials:
βˆa ≡ Pn
{
1e′(E)
fˆ(e′|C0)
Mˆ ratioY
}
βˆb ≡ Pn
{
1e(E)
fˆ(e|C0)
(Cˆratio1 )
−1Eˆ(Y |M,C1, e′,C0)
}
,
which again involve plugging in estimated regression models and density curves fˆ(e|M,C1,C0),
fˆ(e|C1,C0), and fˆ(e|C0). Note that βˆa and βˆb depend only on a subset of the models in the
multiple-robustness conditions (a) and (b), respectively. It follows that βˆa will generally be con-
sistent only if a slightly weaker form of (a) holds, where B′W need not be correctly specified.
Similarly, βˆb will be consistent only if a slightly weaker form of (b) holds, where B′′W need not
13
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be correctly specified. In settings with practical violations of positivity, stability of both estima-
tors can be improved using the stabilization technique given in Section 4.2.
5. SIMULATION STUDY
We report results for a simulation study in which we generated 1000 data sets of size 1000 from
the following models:
C0 ∼ U(0, 2)
E|C0 ∼ Bernoulli
(
1− (1 + exp(0.9 + 0.3C0))−1
)
C1 =

0.8
0.6
−0.3
+

1
0.1
0.2
C0 +

0.5
−0.4
0.5
E +

−0.1
0.8
−0.2
C0E +N (0, I)
M = −0.5− 0.2C0 + 0.3E + [−0.2, 0.1, 0.5]C1 + [0.4, 0, 0]EC1 +N(0, 1)
Y = 0.2 + 0.2C0 + 0.6E + [1, 0.7, 0.3]C1 − 0.9M − 0.8EM +N(0, 1).
In order to investigate the impact of model misspecification, we computed each of the four esti-
mators given above, βˆmr, βˆmle βˆa, and βˆb, under the four parametric models,Ma,Mb,Mc, and
Mint. ModelsMa,Mb, andMc were specified such that statements (a)-(c) in Section 4.2 cor-
responding to their respective subscripts held, but the models for the remaining estimands were
incorrectly specified. For instance, under Ma, models θWM and fWE|C0 are correctly specified,
while BW and θWC1 are not. The intersection model uses correctly-specified working models. All
models were fit by maximum likelihood. The stabilization technique described in Section 4.2
was used to adjust propensity scores. We used the following working models, subscripted C for
correctly specified and I for incorrectly specified:
fWE|C0:
Correct: logit PrC{E = 1|C0} = [1, C0]αC
Incorrect: Φ−1(PrI{E = 1|C0}) = [1, C0]αI
BW :
Correct: EC [Y |M,C1, E, C0] = [1, C0, E,C1,M,EM ]ηC
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Incorrect: EI [Y |M,C1, E, C0] = [1, C0, E,C1,M ]ηI
θWC1:
Correct: Cratio;W1 = PrC(E = e|C1, C0)/PrC(E = e′|C1, C0) × PrC(E = e′|C0)PrC(E =
e|C0), which depends on the correctly-specified fWE|C0 model and the correctly-specified model
logit PrC{E = 1|C1, C0} = [1, C0, C20 ,C1, C0C1]λC ;
B′′C(e
′, e, C0) = EC [EC{EC(Y |M,C1, e′, C0)|C1, e, C0}|e′, C0], which depends on the correctly-
specified BW model and the correctly-specified models EC [C1j|E,C0] = [1, C0, E, C0E]δj;C ∀
j ∈ {1, 2, 3} and EC [M |C1, E, C0] = [1, C0, E,C1, EC11]ζC .
Incorrect: Cratio;W,I1 = PrI(E = e|C1, C0)/PrI(E = e′|C1, C0)×PrC(E = e′|C0)/PrC(E =
e|C0), which depends on the correctly-specified fWE|C0 model and the incorrectly-specified model
logit PrI{E = 1|C1, C0} = [1, C0,C1]λI ;
B′′I (e
′, e, C0) = EI [EC{EI(Y |M,C1, e′, C0)|C1, e, C0}|e′, C0], which depends on the incorrectly-
specified BW model, the correctly-specified working mean model for M used for B′′C(e
′, e, C0)
above, and the incorrectly-specified model EI [C1j|E,C0] = [1, C0, E]δj,I , since θWC1 is only
misspecified in setting (a), under which BW is also misspecified and θWM is correctly specified.
θWM :
Correct: M ratio;W,C = PrC(E = e|M,C1, C0)/PrC(E = e′|M,C1, C0) × PrC(E = e′|
C1, C0)/PrC(E = e|C1, C0), which depends on the correctly-specified model logit PrC{E =
1|M,C1, C0} = [1, C0, C20 ,C1, C0C1, C11C1,M,C11M ]γC and the correctly-specified logistic
model used for Cratio;W1 above;
B′C(C1, e
′, e, C0) = EC{EC(Y |M,C1, e′, C0)|C1, e, C0} depends on the correctly-specifiedBW
model and the correctly-specified mean model for M used for B′′C(e
′, e, C0) above.
Incorrect: M ratio;W,I = PrI(E = e|M,C1, C0)/PrI(E = e′|M,C1, C0) × PrC(E = e′|C1,
C0)/PrC(E = e|C1, C0), which depends on the correctly-specified logistic model for PrC{E =
1|C1, C0} and the incorrectly-specified model logit PrI{E = 1|M,C1, C0} = [1, C0,C1,M ]γI ;
B′I(C1, e
′, e, C0) = EI{EC(Y |M,C1, e′, C0)|C1, e, C0}, which depends on the incorrectly-spec-
ified model EI [M |C1, E, C0] = [1, C0, E,C1]ζI and the correctly-specified model BW,C , since
θWM is only misspecified in setting (c), under which B
W is correctly specified.
The results are summarized in the plot displayed in Figure 2 that shows the four point esti-
mates under each model and their corresponding 95% confidence intervals. The point estimates
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Figure 2: Simulation results for n=1000. Monte Carlo point estimates and confidence intervals
of each of the four PEMY -specific estimators are given under Mint, Ma, Mb, and Mc. The
horizontal dashed line is through the true parameter value, β0.
are the Monte Carlo means of the 1000 samples and the confidence intervals are the values within
t999,0.975 times the corresponding Monte Carlo standard errors of the point estimates. The confi-
dence intervals correspond to t tests of H0 : βˆ = β0 ≡ 2.678, hence the confidence intervals not
containing β0, represented by the horizontal dashed line, correspond to rejection of H0.
All estimators are consistent underMint. Besides βˆmr, βˆa is the only consistent estimator
underMa, βˆb is the only consistent estimator underMb, and βˆmle is the only consistent estimator
underMc. βˆmr is consistent under all models. Therefore, in moderate to large samples, we expect
to reject H0 at the nominal α = 0.05 level for none of the estimators underMint, only for βˆb and
βˆmle underMa, only for βˆa and βˆmle underMb, and only for βˆa and βˆb underMc.
The results illustrate quite well the multiple-robustness property of βˆmr. As predicted, while
the other estimators failed to estimate β0 without statistically-significant bias, the tests for βˆmr
failed to reject under every model. For the other estimators, the tests never rejected underMint
and their corresponding models where the misspecified components did not factor into estimation,
as expected. That is, the test for βˆa did not reject underMa, the test for βˆb did not reject under
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Mb, and the test for βˆmle did not reject underMc. The tests did reject, however, under the other
models, with the exception of βˆc underMb. Thus, all estimators other than βˆmr were significantly
biased under at least one model.
We do see a tradeoff between efficiency and robustness; in all settings, βˆmle and βˆb perform
best in terms of efficiency, with a slight advantage going to βˆmle. As such, a reasonable strategy
may be to use these estimators in concert initially to diagnose model specification, and then select
the most efficient estimator that appears to agree with the multiply-robust estimator, possibly βˆmr
itself.
Other sample sizes were also explored. At n = 500, asymptotic results began to come into
focus, though a few of the tests expected to reject looked to be slightly underpowered due to
the sample not being large enough. Still, the multiply-robust estimator outperformed the other
estimators at this sample size in terms of robustness. At n = 5000, confidence intervals were
tighter, as expected, but t test results were the same as those at n = 1000. The simulation
study with n = 1000 is comparable to our data analysis in terms of sample size; every treatment
comparison consisted of at least 1000 patients.
6. HARVARD PEPFAR NIGERIA ANALYSIS
We now present results of the Harvard PEPFAR data analysis. The data set consisted of 9968
complete observations, i.e., observations with no missing variables, which was 41.9% of the
entire data set. We first consider the path-specific effect of treatment regimen assignment on
virologic failure through adherence, expressed on the log-risk ratio scale. We used each of the
four estimators for β0 from Section 4, and in each case, δ0 was estimated using only a subset
of the models used to estimate β0. In particular, the doubly-robust estimator (Bang and Robins,
2005) was used to estimate δ0 when contrasted with βˆb and the multiply-robust estimator, βˆmr;
the inverse-probability-weighted estimator (IPW) (Horvitz and Thompson, 1952) was used to es-
timate δ0 when contrasted with βˆa; and the MLE was used to estimate δ0 when contrasted with the
MLE for the β0, βˆmle. Accordingly, let PˆEMY ;mle denote the effect estimate using βˆmle, PˆEMY ;a
denote the effect estimate using βˆa, PˆEMY ;b denote the effect estimate using βˆb, and PˆEMY ;mr de-
note the effect estimate using βˆmr. We computed all four estimates and corresponding bootstrap
confidence intervals for each pairwise comparison of treatments. The wild bootstrap (Mammen,
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1993) with weights sampled from Exp(1) was used to account for instability of resamples due
to a small number of cases in some strata of E. Results are summarized in Figure 1 of the
supplementary materials.
PˆEMY ;a agreed with PˆEMY ;mr across all comparisons, suggesting that it did not suffer much
from model misspecification, or at least any worse than did PˆEMY ;mr. It also proved to be the
more efficient estimator in this setting, with confidence intervals that were narrower than those
of PˆEMY ;mr, and comparable to those of PˆEMY ;mle, which did not appear to be as robust. Thus,
we chose to perform inference using PˆEMY ;a for this portion of the analysis.
Recall that the treatment regimens were coded in descending order of magnitude of their
total effects on risk of virologic failure, i.e., they were coded in ascending order of counterfactual
risk of virologic failure had everyone been assigned to that treatment, since a lower counterfactual
risk of failure corresponds to a higher magnitude of total effect. Because in practice we are more
interested in learning how less-effective treatments can be improved, we only consider the higher-
coded treatment in a pair as the baseline, e′. Using this ordering, the path-specific effect gives
the improvement over the total effect of the less-effective treatment when intervening to make
patients adhere as if they were on the more-effective treatment, but had the toxicity and direct
effectiveness of the less-effective treatment.
We are primarily interested in the proportion of the total effect attributable to the mediated
effect, i.e., the percent mediated by PEMY . If this proportion is close to or exceeds one, we can
conclude that the drugs themselves likely have the same effectiveness on virologic failure, and
that it is their differential effect on adherence not due to toxicity that is driving the difference in
total effects. If, on the other hand, this proportion is small or negative, we can only say that the
difference in total effects is not driven by a difference in effects through PEMY . It may be the
case that the efficacies of the drugs themselves do, in fact, differ, or that the difference in total
effects is driven by the differential effect on adherence due to toxicity, but we cannot confirm
either. Table 2 shows PˆEMY ;a divided by the total effect estimates, which are also on the log-risk
ratio scale and are estimated by IPW. Superscripts indicate the comparisons with significant and
marginally-significant path-specific effects. Due to the treatment coding, the denominators of
the Table 2 values are always negative. Thus, a negative path-specific effect will be in the same
direction as the total effect, and hence will explain a positive proportion of it.
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Table 2: Proportion of total effect on virologic failure due to PEMY -specific effect
Baseline treatment
Comparison trt 2 3 4 5
1 0.41† 0.21 -0.059 -0.068∗
2 - 0.13 -0.49∗ -0.20∗
3 - - -0.57† -0.13∗
4 - - - -0.027†
NOTE: ∗Significant path-specific effect (α = 0.05). †Marginally-significant path-specific effect
(α = 0.1).
Note that all significant and marginally-significant proportions of total effects due to the ef-
fects through PEMY were negative apart from the one comparing treatment 1 (TDF+3TC/FTC+
EFV) to baseline treatment 2 (d4T+3TC+NVP). This occurs when the PEMY -specific effect
estimate is in the opposite direction of the total effect estimate, suggesting that directionally-
opposite effects through other pathways overwhelm our estimated effect, and that the total effect
would have been even greater if not for the PEMY -specific effect. For example, had the PEMY -
specific effect been null in the case comparing treatment 3 (AZT+3TC+EFV) with treatment 5
(TDF+3TC/FTC+NVP), we estimate that the total effect would have been 13% larger. The effect
of treatment 3 is stronger than 5 not because of its effect through PEMY , but in spite of it. All
differences between treatment 5 and another treatment, and all differences between treatment 4
(AZT+3TC+NVP) and another treatment besides 1 were observed to exhibit this phenomenon as
well.
Now consider the exception noted above: the comparison of treatment 1 (TDF+3TC/FTC+
EFV) to baseline treatment 2 (d4T+3TC+NVP). We saw a marginally-negative effect, which
would have the following interpretation: the effect of treatment 2 on the risk of virologic failure
would be improved by patients adhering as if they were assigned to treatment 1, but still had the
same toxicity that they did on treatment 2. Unfortunately, treatment 2 is known to have toxicities
that were not measured in this data set that are likely to also be affected by underlying biological
causes of virologic failure. This interpretation cannot even be considered to be valid for the effect
through these unmeasured toxicities, since they induce unmeasured confounding that once again
renders this effect unidentifiable. If there were no unmeasured toxicities, we would interpret this
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effect as accounting for an estimated 41% of the differences in total effects between treatments 1
and 2.
In conclusion, of the significant PEMY -specific effects we observed, all apart from those
involving unmeasured toxicities were countervailing to the total effect. This means that for these
treatment pairs, the differences in their total effects on virologic failure would have been even
greater if not for the effect along PEMY . Thus, the effect through PEMY does not explain the
differential effects on virologic failure, and in some cases actually works against them. As men-
tioned above, the differential effects may instead be due to the drugs themselves differing in
efficacy, or they may be driven by the differential effects on adherence due to toxicity, but such
hypotheses require further investigation beyond the scope of our analysis.
We now consider the path-specific effect of treatment regimen assignment on log CD4 count,
expressed on the mean difference scale. We again analyzed the four estimators given in Section
4. This time PˆEMY ;a and PˆEMY ;b were drastically less efficient than PˆEMY ;mle and PˆEMY ;mr.
One possible explanation for this is that the density of log CD4 count was less concentrated
around zero, making PˆEMY ;a and PˆEMY ;b more sensitive to small weights. PˆEMY ;mle disagreed
with PˆEMY ;mr on several occassions, so PˆEMY ;mr was the best choice in terms of achieving both
robustness and efficiency. It is worth noting that the linear outcome model for CD4 count did not
seem to suffer too much from misspecification, while the logistic outcome model for virologic
failure did. Results are summarized in Figure 2 of the supplementary materials.
Table 3 shows PˆEMY ;mr divided by the total effect estimates, which are also on the log-risk
ratio scale and are estimated using doubly-robust estimators. As before, we are interested in
Table 3: Proportion of total effect on CD4 count due to PEMY -specific effect
Baseline treatment
Comparison trt 3 1 5 2
4 0.48∗ 0.095 -0.045† 0.036
3 - -0.47 -0.13 0.030
1 - - -0.080 0.062
5 - - - 0.099
NOTE: ∗Significant path-specific effect (α = 0.05). †Marginally-significant path-specific effect
(α = 0.1).
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learning how the less-effective treatment can be improved, but now less-effective is in terms of
CD4 count. Since the order of the effectiveness of the treatments for CD4 count is not the same as
the order for virologic failure, the treatments which should be considered the comparison versus
baseline level in a pair no longer correspond to the treatment coding. The order of the treatments
in the margins of Table 3 is rearranged to reflect this different ordering of effectiveness. The de-
nominator for each of the values in the table is positive, since a higher counterfactual CD4 count
corresponds to a higher magnitude of total effect. Therefore, positive proportions correspond to
positive path-specific effects, and negative proportions correspond to countervailing path-specific
effects.
The path-specific effect was found to be significant for only one of the pairwise compar-
isons: treatment 4 (AZT+3TC+NVP) vs. treatment 3 (AZT+3TC+EFV). This effect is estimated
to be in the positive direction, therefore we conclude that the effect of treatment 3 on CD4 count
would be improved by patients adhering as if they were assigned to treatment 4 but without nec-
essarily altering toxicity experienced under treatment 3 that they did on treatment 3. The effect
through this pathway accounted for almost half of the total effect at an estimated 48%. Thus,
if one were interested in improving the effect of AZT+3TC+EFV on CD4 count, it would be
worthwhile to examine what mechanisms other than toxicity may be implicated in differential
adherence rates between these two regimens. The PEMY -specific effect comparing treatments 4
and 5 (TDF+3TC/FTC+NVP) was found to be marginally-significantly less than zero. Thus, the
difference in total effects of these two treatments is not attributable to their differential effect on
adherence not due to toxicity, as the effect through this pathway was in fact in the opposite direc-
tion. Rather, this difference was due to differential effects through other pathways as previously
described.
7. DISCUSSION
In the PEPFAR case study, we observed an interesting trend of countervailing effects alongPEMY
to the total effects on virologic failure for most treatment comparisons, meaning that the differ-
ences in the total effects of treatment assignment would have been even greater if not for the
effects along PEMY . While this does not help explain why the treatment assignment effects are
different (or at least different in the direction that we observe), it does suggest a method for im-
21
Hosted by The Berkeley Electronic Press
proving the regimens that we observed to have greater effects on virologic failure. For a treatment
comparison with a significant PEMY -specific effect, if we could identify what is different about
the more effective drug regimen that is causing people to not adhere to it as well, then we could
potentially eliminate this mechanism in order to reduce the countervailing PEMY -specific effect
and consequently improve its total effect on virologic failure.
A countervailingPEMY -specific effect on CD4 count was also observed between AZT+3TC+
NVP and TDF+3TC/FTC+NVP, which has the same interpretation as the countervailing ef-
fects on virologic failure. On the other hand, almost half of the difference in the effects of
AZT+3TC+EFV and AZT+3TC+NVP on CD4 count was found to be attributable to the effect
through adherence, but not toxicity. This suggests that the effect of AZT+3TC+EFV on CD4
count could be improved up to that of AZT+3TC+NVP if one could identify and eliminate the
mechanisms driving the difference in these treatments’ effects on adherence. In the other treat-
ment comparisons, none of the differences in total effects on CD4 count were found to be at-
tributable to an effect through PEMY . Overall, we have achieved an enhanced understanding of
the role of adherence in the effects of the five ART regimens considered on both virologic failure
and CD4 count.
The most significant methodologic contribution of this paper is the extension of mediation
analysis methods to settings in which the NDE and NIE may not be identified, viz. settings
with unmeasured confounding and exposure-induced confounding of the mediator. We present
conditions under which the PEMY -specific effect is nonparametrically identified as well as four
estimators, including an efficient estimator that is multiply robust to model misspecification for
settings where nonparametric estimation is not feasible.
Often effects of adherence are evaluated regarding the treatment assignment as an instrumen-
tal variable, relying on an assumption of no direct effect of assignment with respect to adherence.
Furthermore, instrumental variable methods rely on an assumption of monotonicity in the effect
of assignment on adherence. However, neither of these assumptions are reasonable in our setting
where we are forced to compare treatments head-to-head rather than to a control exposure level.
This paper suffers from a few limitations. One is that our identifiability assumptions, though
weaker than those of the Markovian model, are still untestable as stated. When possible, we can
embed our mediation problem in a larger model represented by a larger graph where treatments
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can be split into a component corresponding to the EMY pathway and a component correspond-
ing to all other pathways. This can provide a testable reformulation of identifying assumptions,
as was done in Robins and Richardson (2010) in simpler mediation contexts. Another limitation
is that this method is not yet equipped to handle missing data. As such, only a complete-case
analysis was conducted for the HIV data, allowing for the possibility of bias due to informative
missingness. Additionally, for both virologic failure and CD4 count outcomes, it is possible that
we are underestimating the effect of substantive interest if adherence over the first six months
plays a large mediating role since we are forced to control for early adherence and can only esti-
mate the effect through adherence over the second six months. Finally, not a limitation, but rather
a caveat, is that the PEMY -specific effect is not a substitute for the NIE. The NIE is not fully cap-
tured by this effect and, in fact, even if the effects along both PEMY and E → C1 → M → Y
are in the same direction, the NIE does not necessarily have to be. Strong assumptions are needed
to draw this conclusion. As such, while often practically meaningful, the PEMY -specific effect
must be interpreted with care and not blindly substituted for the NIE.
Future directions for this work would, of course, include adjusting the method to account
for missing data, which could improve the analysis conducted in this paper. Another important
extension would be to the full longitudinal case, with repeated exposures, mediators, and con-
founders. Shpitser (2013) gives the identifying functional for the analog to the PEMY -specific
effect in this setting, but no estimation strategy exists as of yet. Finally, it is not uncommon for a
mediator to be measured with error, which tends to induce bias as shown by VanderWeele et al.
(2012). It would be valuable to adapt the methods of Tchetgen Tchetgen and Lin (2012) for
handling this problem to our setting. Alternatively, parametric approaches have been suggested
(Valeri et al., 2014) that could also potentially be adapted.
8. SUPPLEMENTARY MATERIALS
All supplementary materials are contained in a single archive and can be obtained via a single
download.
Proofs and theoretical results: We prove Theorem 1, derive the four estimation strategies, de-
rive the efficient influence function of β0, and a prove its robustness. (PDF file)
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Additional stabilization technique for the multiply-robust estimator: We present an additional
method to account for instability of the multiply-robust estimator due to near-positivity vi-
olations. (PDF file)
Plots comparing estimators in the PEPFAR Nigeria study: Plots summarizing the estimation
results for the PEMY -specific effect on virologic failure and CD4 count using the four
estimators. These plots were used to assess model misspecification and select the most
appropriate estimator. (PDF file)
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A. PROOFS AND THEORETICAL RESULTS
A.1 Identification Result Proof
Proof of Theorem 1.
β0 ≡ E[Y (M(C1(e′), e),C1(e′), e′)]
=
∫
c0,c1,m,y
ydFY (M(C1(e′),e),C1(e′),e′),M(C1(e′),e),C1(e′),C0(y,m, c1, c0)
=
∫∫
c0,c1,m,y
ydFY (m,e′),M(c1,e),C1(e′)|C0(y,m, c1|c0)dFC0(c0)
=
∫∫∫
c0,c1,m,y
ydFY (m,e′),C1(e′)|C0(y, c1|c0)dFM(c1,e)|C0(m|c0)dFC0(c0) (2)
=
∫∫∫
c0,c1,m,y
ydFY (m,e′),C1(e′)|E,C0(y, c1|e′, c0)dFM(c1,e)|C0(m|c0)dFC0(c0) (3)
=
∫∫∫
c0,c1,m,y
ydFY (m),C1|E,C0(y, c1|e′, c0)dFM(c1,e)|C0(m|c0)dFC0(c0) (4)
=
∫∫∫∫
c0,c1,m,y
ydFY (m)|C1,E,C0(y|c1, e′, c0)dFM(c1,e)|C0(m|c0)dFC1|E,C0(c1|e′, c0)dFC0(c0)
=
∫∫∫∫
c0,c1,m,y
ydFY (m)|M,C1,E,C0(y|m, c1, e′, c0)dFM(c1,e)|C1,E,C0(m|c1, e, c0)
× dFC1|E,C0(c1|e′, c0)dFC0(c0) (5)
=
∫∫∫∫
c0,c1,m,y
ydFY |M,C1,E,C0(y|m, c1, e′, c0)dFM |C1,E,C0(m|c1, e, c0)
× dFC1|E,C0(c1|e′, c0)dFC0(c0), (6)
where (2) follows from {Y (m, e′),C1(e′)}⊥⊥M(c1, e)|C0, (3) follows from {Y (m, e′),C1(e′)}
⊥⊥E|C0, (4) follows by consistency, (5) follows from Y (m)⊥⊥M |C1, E,C0 and M(c1, e)⊥⊥
{C1, E}|C0, and (6) follows by consistency.
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A.2 Derivation of Estimation Strategies
A.2.1 Maximum Likelihood Estimator
The maximum likelihood estimator arises from the alternative representation of (1):∫∫∫
m,c1,c0
E(Y |m, c1, e′, c0)dFM |C1,E,C0(m|c1, e, c0)dFC1|E,C0(c1|e′, c0)dFC0(c0)
= E(E(E(E(Y |M,C1, e′,C0)|C1, e,C0)|e′,C0)).
We replace the inner three expectations with their arguments’ means under the empirical laws
fˆC1|e′,C0 , fˆM |C1,e,C0 , and fˆY |M,C1,e′,C1 respectively, and compute the empirical mean. Thus, we
have
βˆmle ≡ Pn
{
Eˆ(Eˆ(Eˆ(Y |M,C1, e′,C0)|C1, e,C0)|e′,C0)
}
.
A.2.2 Estimator a
βˆa arises from another alternative representation of (1):∫∫∫
m,c1,c0
E(Y |m, c1, e′, c0)dFM |C1,E,C0(m|c1, e, c0)dFC1|E,C0(c1|e′, c0)dFC0(c0)
=
∑
e∗∈{e′,e}
∫
y,m,c1,c0
y
1e′(e
∗)
f(e′|c0)
f(m|c1, e, c0)
f(m|c1, e∗, c0)dFY,M,C1,E,C0(y,m, c1, e
∗, c0)
= E
{
Y
1e′(E)
f(e′|C0)
f(M |C1, e,C0)
f(M |C1, e′,C0)
}
.
We simply plug in the empirical laws, fˆE=0|C0 , fˆM |C1,e,C0 , and fˆM |C1,e′,C0 for fE=0|C0 , fM |C1,e,C0 ,
and fM |C1,e′,C0 respectively, and compute the empirical mean. Thus, we have
βˆa ≡ Pn
{
Y
1e′(E)
fˆ(e′|C0)
fˆ(M |C1, e,C0)
fˆ(M |C1, e′,C0)
}
.
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A.2.3 Estimator b
βˆb arises from a third representation of (1):∫∫∫
m,c1,c0
E(Y |m, c1, e′, c0)dFM |C1,E,C0(m|c1, e, c0)dFC1|E,C0(c1|e′, c0)dFC0(c0)
=
∑
e∗∈{e′,e}
∫
m,c1,c0
E(Y |M,C1, e′,C0) 1e(e
∗)
f(e∗|c0)
f(c1|e′, c0)
f(c1|e∗, c0)dFM,C1,E,C0(m, c1, e
∗, c0)
= E
[
1e(E)
f(e|C0)
f(C1|e′,C0)
f(C1|e,C0) E(Y |M,C1, e
′,C0)
]
.
Again, we plug in the empirical laws fˆC1|e′,C0 , fˆC1|e,C0 , and fˆE=1|C0 for fC1|e′,C0 , fC1|e,C0 , and
fE=1|C0 , respectively, replace E(Y |M,C1, e′,C0) with Eˆ(Y |M,C1, e′,C0), the expectation of
Y under the empirical law fˆY |M,C1,e′,C0 , and compute the empirical mean. Thus, we have
βˆb ≡ Pn
{
1e(E)
fˆ(e|C0)
fˆ(C1|e′,C0)
fˆ(C1|e,C0)
Eˆ(Y |M,C1, e′,C0)
}
.
We develop the multiply-robust estimator and prove its robustness properties in the following two
sections.
A.3 Derivation of the Influence Function
Theorem 2. The efficient influence function of β0 in modelMnonpar is given by
V eff (β0) =
1e′(E)f(M |e,C1,C0)
f(M |e′,C1,C0)f(e′|C0) {Y −B(M,C1, e
′,C0)}
+
1e(E)f(C1|e′,C0)
f(C1|e,C0)f(e|C0) {B(M,C1, e
′,C0)−B′(C1, e′, e,C0)}
+
1e′(E)
f(e′|C0) {B
′(C1, e′, e,C0)−B′′(e′, e,C0)}+ {B′′(e′, e,C0)− β0},
implying that the asymptotic variance of a regular, asymptotically linear (RAL) estimator of β0
in modelMnonpar can be no smaller than E{V eff (β0)2}−1, the semiparametric efficiency bound
for the model.
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βˆmr is obtained simply by solving the estimating equation V eff (β0) for β0. Since our model
is nonparametric, the asymptotic variance is the same for any estimator inMnonpar so long as it
is RAL. Furthermore, since all such estimators share the common influence function V eff (β0),
they also share a common asymptotic expansion, viz. n1/2(βˆ0 − β0) = n1/2PnV eff (β0) + op(1),
where Pn denotes the empirical mean.
Proof. Let ν denote the appropriate dominating measure or product measure corresponding to
each combination of random variables. Let FO;t = FY |M,C,E,C0;tFM |C1,E,C0;tFC1|E,C0;tFE|C0;tFC0;t
denote a one-dimensional regular parametric submodel ofMnonpar with FO,0 = FO, and let
βt = β0(FO;t) = Et(Y (M(e,C1(e′)),C1(e′), e′))
=
∫
m,c1,c0
Et(Y |m, c1, e′, c0)ft(M = m|c1, e, c0)ft(C1 = c1|e′, c0)ft(C0 = c0)dν(m, c1, c0)
and UO =
Ot=0ft(O)
f(O)
be the score for O. Then
∂βt
∂t
∣∣∣∣
t=0
=∫
m,c1,c0
Ot=0Et(Y |m, c1, e′, c0)f(M = m|c1, e, c0)f(C1 = c1|e′, c0)f(C0 = c0)dν(m, c1, c0)
(7)
+
∫
m,c1,c0
E(Y |m, c1, e′, c0)Ot=0ft(M = m|c1, e, c0)f(C1 = c1|e′, c0)f(C0 = c0)dν(m, c1, c0)
(8)
+
∫
m,c1,c0
E(Y |m, c1, e′, c0)f(M = m|c1, e, c0)Ot=0ft(C1 = c1|e′, c0)f(C0 = c0)dν(m, c1, c0)
(9)
+
∫
m,c1,c0
E(Y |m, c1, e′, c0)f(M = m|c1, e, c0)f(C1 = c1|e′, c0)Ot=0ft(C0 = c0)dν(m, c1, c0),
(10)
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where
(7) =
∫
m,c1,c0
Ot=0Et(Y |m, c1, e′, c0)f(M = m|c1, e, c0)f(C1 = c1|e′, c0)f(C0 = c0)dν(m, c1, c0)
=
∫
m,c1,c0
∫
y
y
{
Ot=0ft(y,m, c1, e′, c0)
f(m, c1, e′, c0)
− f(y,m, c1, e
′, c0)Ot=0ft(m, c1, e′, c0)
f(m, c1, e′, c0)2
}
dν(y)
× f(M = m|c1, e, c0)f(C1 = c1|e′, c0)f(C0 = c0)dν(m, c1, c0)
=
∫
y,m,c1,c0
{
y
Ot=0ft(y,m, c1, e′, c0)
f(m, c1, e′, c0)
− Ot=0ft(m, c1, e
′, c0)
f(m, c1, e′, c0)
E(Y |m, c1, e′, c0)f(y|m, c1, e′, c0)
}
× f(M = m|c1, e, c0)f(C1 = c1|e′, c0)f(C0 = c0)dν(y,m, c1, c0)
=
∫
y,m,c1,e∗,c0
{
y
Ot=0ft(y,m, c1, e∗, c0)
f(m, c1, e′, c0)
− Ot=0ft(m, c1, e
∗, c0)
f(m, c1, e′, c0)
E(Y |m, c1, e′, c0)f(y|m, c1, e′, c0)
}
× 1e′(e∗)f(M = m|c1, e, c0)f(C1 = c1|e′, c0)f(C0 = c0)dν(y,m, c1, e∗, c0)
=E
[
1e′(E)f(M |C1, e′,C0)f(C1|e′,C0)f(C0)
f(Y,M,C1, E,C0)
×
{
Y
Ot=0ft(Y,M,C1, E,C0)
f(M,C1, e′,C0)
− f(Y |M,C1, e′,C0)Ot=0ft(M,C1, E,C0)
f(M,C1, e′,C0)
B(M,C1, e
′,C0)
}]
=E
[
1e′(E)f(M |C1, e,C0)f(C1|e′,C0)f(C0)
f(Y,M,C1, E,C0)f(M,C1, e′,C0)
{Y Ot=0ft(Y,M,C1, E,C0)
−[Ot=0ft(Y,M,C1, E,C0)− f(M,C1, e′,C0)Ot=0ft(Y |M,C1, E,C0)]B(M,C1, e′,C0)}
]
=E
[
Ot=0ft(Y,M,C1, E,C0)
f(Y,M,C1, E,C0)
× 1e′(E)f(M |C1, e,C0)
f(M |C1, e′,C0)f(E = e′|C0){Y −B(M,C1, e
′,C0)}
]
+
∫
m,c1,c0
f(c1|e′, c0)f(m|c1, e, c0)f(c0)Ot=0
{∫
y
ft(y|m, c1, e′, c0)dν(y)
}
×B(m, c1, e′, c0)dν(m, c1, c0)
=E
[
UO
1e′(E)f(M |C1, e,C0)
f(M |C1, e′,C0)f(E = e′|C0){Y −B(M,C1, e
′,C0)}
]
,
(8) =
∫
m,c1,c0
E(Y |m, c1, e′, c0)
{
Ot=0ft(m, c1, e, c0)
f(c1, e, c0)
− Ot=0ft(c1, e, c0)f(m, c1, e, c0)
f(c1, e, c0)2
}
× f(c1|e′, c0)f(c0)dν(m, c1, c0)
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=∫
m,c1,c0
E(Y |m, c1, e′, c0)Ot=0ft(m, c1, e, c0)
f(c1, e, c0)
f(c1|e′, c0)f(c0)dν(m, c1, c0)
−
∫
c1,c0
Ot=0ft(c1, e, c0)
f(c1, e, c0)
E(E(Y |m, c1, e′, c0)|c1, e, c0)f(c1|e′, c0)f(c0)dν(c1, c0)
=
∫
m,c1,c0
f(c1|e′, c0)f(c0)
f(c1, e, c0)
{
Ot=0ft(m, c1, e, c0)E(Y |m, c1, e′, c0)
− Ot=0ft(c1, e, c0)f(m|c1, e, c0)B′(c1, e′, e, c0)
}
dν(m, c1, c0)
=
∫
m,c1,c0
f(c1|e′, c0)
f(c1|e, c0)f(e|c0)
{
Ot=0ft(m, c1, e, c0)E(Y |m, c1, e′, c0)
− [Ot=0ft(m, c1, e, c0)− f(c1, e, c0)Ot=0ft(m|c1, e, c0)]B′(c1, e′, e, c0)
}
dν(m, c1, c0)
=
∫
m,c1,c0
Ot=0ft(m, c1, e, c0)
f(c1|e′, c0)
f(c1|e, c0)f(e|c0) {E(Y |m, c1, e
′, c0)−B′(c1, e′, e, c0)} dν(m, c1, c0)
+
∫
c1,c0
f(c1|e′, c0)f(c0)Ot=0
∫
m
ft(m|c1, e, c0)dν(m)B′(c1, e′, e, c0)dν(c1, c0)
=
∫
m,c1,c0
{∫
y
f(y|m, c1, e, c0)dν(y)Ot=0ft(m, c1, e, c0)
+Ot=0
∫
y
ft(y|m, c1, e, c0)dν(y)f(m, c1, e, c0)
}
f(c1|e′, c0)
f(c1|e, c0)f(e|c0)
× {E(Y |m, c1, e′, c0)−B′(c1, e′, e, c0)} dν(m, c1, c0)
=
∫
y,m,c1,c0
Ot=0ft(y,m, c1, e, c0)
f(c1|e′, c0)
f(c1|e, c0)f(e|c0)
× {E(Y |m, c1, e′, c0)−B′(c1, e′, e, c0)} dν(y,m, c1, c0)
=
∫
y,m,c1,e∗,c0
Ot=0ft(y,m, c1, e∗, c0)
1e(e
∗)f(c1|e′, c0)
f(c1|e, c0)f(e|c0)
× {E(Y |m, c1, e′, c0)−B′(c1, e′, e, c0)} dν(y,m, c1, e∗, c0)
=E
[
UO
1e(E)f(C1|e′,C0)
f(C1|e,C0)f(e|C0) {E(Y |M,C1, e
′,C0)−B′(C1, e′, e,C0)}
]
,
(9) =
∫
m,c1,c0
E(Y |m, c1, e′, c0)f(m|c1, e, c0)
{
Ot=0ft(c1, e′, c0)
f(e′, c0)
− Ot=0ft(e
′, c0)f(c1, e′, c0)
f(e′, c0)2
}
30
http://biostats.bepress.com/harvardbiostat/paper186
× f(c0)dν(m, c1, c0)
=
∫
c1,c0
E(E(Y |M,C1, e′,C0)|c1, e, c0)
{
Ot=0ft(c1, e′, c0)
f(e′, c0)
− Ot=0ft(e
′, c0)
f(e′, c0)
f(c1|e′, c0)
}
× f(c0)dν(c1, c0)
=
∫
c1,c0
B′(c1, e′, e, c0)
Ot=0ft(c1, e′, c0)
f(e′, c0)
f(c0)dν(c1, c0)
−
∫
c0
E(E(E(Y |M,C1, e′,C0)|C1, e,C0)|e′, c0)Ot=0ft(e
′, c0)
f(e′, c0)
f(c0)dν(c0)
=
∫
c1,c0
f(c0)
f(e′, c0)
{Ot=0ft(c1, e′, c0)B′(c1, e′, e, c0)
−Ot=0ft(e′, c0)f(c1|e′, c0)B′′(e′, e, c0)} dν(c1, c0)
=
∫
c1,c0
1
f(e′|c0) {Ot=0ft(c1, e
′, c0)B′(c1, e′, e, c0)
− [Ot=0ft(c1, e′, c0)− Ot=0ft(c1|e′, c0)f(e′, c0)]B′′(e′, e, c0)} dν(c1, c0)
=
∫
c1,c0
1
f(e′|c0)Ot=0ft(c1, e
′, c0) {B′(c1, e′, e, c0)−B′′(e′, e, c0)} dν(c1, c0)
+
∫
c0
f(c0)Ot=0
∫
c1
ft(c1|e′, c0)dν(c1)B′′(e′, e, c0)dν(c0)
=
∫
c1,c0
1
f(e′|c0)

∫
y,m
f(y,m|c1, e′, c0)dν(y,m)Ot=0ft(c1, e′, c0)
+Ot=0
∫
y,m
ft(y,m|c1, e′, c0)dν(y,m)f(c1, e′, c0)
 {B′(c1, e′, e, c0)−B′′(e′, e, c0)} dν(c1, c0)
=
∫
y,m,c1,c0
Ot=0ft(y,m, c1, e′, c0)
f(e′|c0) {B
′(c1, e′, e, c0)−B′′(e′, e, c0)} dν(y,m, c1, c0)
=
∫
y,m,c1,e∗,c0
Ot=0ft(y,m, c1, e∗, c0)
1e′(e
∗)
f(e′|c0) {B
′(c1, e′, e, c0)−B′′(e′, e, c0)} dν(y,m, c1, e∗, c0)
=E
[
UO
1e(E
′)
f(e′|C0) {B
′(c1, e′, e,C0)−B′′(e′, e,C0)}
]
,
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and
(10) =
∫
c0
E(E(E(Y |M,C1, e′,C0)|C1, e,C0)|e′,C0)Ot=0ft(c0)dν(c0)− β0EUO
=
∫
c0

∫
y,m,c1,e∗
f(y,m, c1, e
∗|c0)dν(y,m, c1, e∗)Ot=0ft(c0)
+Ot=0
∫
y,m,c1,e∗
ft(y,m, c1, e
∗|c0)dν(y,m, c1, e∗)f(c0)
B′′(e′, e, c0)dν(c0)− E[UOβ0]
=
∫
y,m,c1,e∗,c0
Ot=0ft(y,m, c1, e∗, c0)B′′(e′, e, c0)dν(y,m, c1, e∗, c0)− E[UOβ0]
=E [UO {B′′(e′, e,C0)− β0}] .
Thus, ∂βt
∂t
∣∣
t=0
= E[UOV eff (β0)] where
V eff (β0) =
1e′(E)f(M |e,C1,C0)
f(M |e′,C1,C0)f(e′|C0) {Y −B(M,C1, e
′,C0)}
+
1e(E)f(C1|e′,C0)
f(C1|e,C0)f(e|C0) {B(M,C1, e
′,C0)−B′(C1, e′, e,C0)}
+
1e′(E)
f(e′|C0) {B
′(C1, e′, e,C0)−B′′(e′, e,C0)}+ {B′′(e′, e,C0)− β0} ,
so if a RAL estimator exists, then V eff (β0) is the corresponding influence function. It is efficient
because the modelMnonpar is nonparametric.
A.4 Multiple-Robustness of the Efficient Influence Function
Let B˜, ˜θM = {M˜ ratio, E˜[B˜(M,C1, e′,C0)|C1, e,C0]}, θ˜C1 = {C˜ratio1 , E˜[B˜′(C1, e, c0)|e′,C0]},
and f˜E|C0 denote limits of the estimators using the working models B
W , θWM , θ
W
C1
, and fWE|C0 .
We have established the following multiply-robust property of V eff :
Theorem 3. The estimating equation V eff (β0, B˜, θ˜M, θ˜C1 , f˜E|C0) is unbiased provided that one
of the following holds:
(a){θ˜M, f˜E|C0} = {θM , fE|C0},
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(b){B˜, θ˜C1 , f˜E|C0} = {B,θC1 , fE|C0}, or
(c){B˜, θ˜C1 , θ˜M} = {B,θC1 ,θM}.
Proof.
EV eff (β0,B˜, θ˜M, θ˜C1 , f˜E|C0) =
E
 ∫
m,c1
M˜ ratio
f˜(e′|C0)
{
B(m, c1, e
′,C0)− B˜(m, c1, e′,C0)
}
× f(m|c1, e′,C0)f(c1|e′,C0)f(e′|C0)dν(m, c1)
+
∫
c1
1
C˜ratio1 f˜(e|C0)
{
E
[
B˜(M, c1, e
′,C0)|c1, e,C0
]
− E˜
[
B˜(M, c1, e
′,C0)|c1, e,C0
]}
× f(c1|e,C0)f(e|C0)dν(c1)
+
f(e′|C0)
f˜(e′|C0)
{
E
[
E˜
[
B˜(M,C1, e
′,C0)|C1, e,C0
]
|e′,C0
]
−E˜
[
E˜
[
B˜(M,C1, e
′,C0)|C1, e,C0
]
|e′,C0
]}
+E˜
[
E˜
[
B˜(M,C1, e
′,C0)|C1, e,C0
]
|e′,C0
]
− E [E [B(M,C1, e′,C0)|C1, e,C0] |e′,C0]

Substituting under (a):
EV eff (β0,B˜, θ˜M, θ˜C1 , f˜E|C0) =
E
 ∫
m,c1
{
B(m, c1, e
′,C0)− B˜(m, c1, e′,C0)
}
f(m|c1, e,C0)f(c1|e′,C0)dν(m, c1)
+
{
E
[
E
[
B˜(M,C1, e
′,C0)|C1, e,C0
]
|e′,C0
]
− E˜
[
E
[
B˜(M,C1, e
′,C0)|C1, e,C0
]
|e′,C0
]}
+E˜
[
E
[
B˜(M,C1, e
′,C0)|C1, e,C0
]
|e′,C0
]
− E [E [B(M,C1, e′,C0)|C1, e,C0] |e′,C0]

= 0
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Substituting under (b):
EV eff (β0,B˜, θ˜M, θ˜C1 , f˜E|C0) =∫
c1
{
E [B(M, c1, e′,C0)|c1, e,C0]− E˜ [B(M, c1, e′,C0)|c1, e,C0]
}
f(c1|e′,C0)dν(c1)
+E
[
E˜ [B(M,C1, e′,C0)|C1, e,C0] |e′,C0
]
− E [E [B(M,C1, e′,C0)|C1, e,C0] |e′,C0]

= 0
Substituting under (c):
EV eff (β0, B˜, θ˜M, θ˜C1 , f˜E|C0) = 0, trivially.
Thus, βˆmr can be shown to be asymptotically normal under each of these scenarios using a
Taylor expansion of PnV eff (βˆmr, Bˆ, θˆM, θˆC1 , fˆE|C0) and applying the central limit theorem to
n−1/2
∑
i V
eff
i (β0, B
∗,θ∗M ,θ
∗
C1
, f ∗E|C0).
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B. ADDITIONAL STABILIZATION TECHNIQUE FOR
THE MULTIPLY-ROBUST ESTIMATOR
This technique is an adaptation of the approach presented by Robins et al. (2007). The idea is to
carefully select regression models and an estimation strategy such that the three terms in βˆmr de-
pending on weights are empirically evaluated as null, leaving the term Bˆ′′(e′, e,C0), which does
not depend on weights. This can be accomplished with the following steps. First, fit propensity
score models to estimate fE|C0 , M
ratio, and Cratio1 . Substitute these estimates into the first term
of βˆmr, and include the result in a set of estimating equation to solve for the Y -regression-model
parameters. Next, plug in all parameters estimated thus far into the second term of βˆmr, and once
again use the result in a set of estimating equations to solve for the M -regression-model parame-
ters. Repeat this step with the third term of βˆmr to solve for theC1-regression-model parameters.
Finally, plugging all of these parameter estimates into βˆmr leaves Bˆ′′(e′, e,C0), as desired. If Y ,
M , and C1 are all scalar, continuous random variables, this procedure is equivalent to repeatedly
fitting regression models with intercepts using weighted least squares with appropriately-chosen
weights.
35
Hosted by The Berkeley Electronic Press
C. PLOTS COMPARING ESTIMATORS IN THE PEPFAR
NIGERIA STUDY
1, 1 1, 2 1, 3 1, 4 1, 5
2, 1 2, 2 2, 3 2, 4 2, 5
3, 1 3, 2 3, 3 3, 4 3, 5
4, 1 4, 2 4, 3 4, 4 4, 5
5, 1 5, 2 5, 3 5, 4 5, 5
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Figure 3: PEMY -specific effects on virologic failure. The plot in each cell represents estimates
for the effect with comparison-level treatment, e, equal to the first index of the cell and baseline-
level treatment, e′ equal to the second index of the cell. That is, comparison level treatment varies
across rows and baseline level treatment varies across columns. Within each plot, the dots and
vertical bars represent point estimates using the four estimators and their corresponding bootstrap
confidence intervals.
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1, 1 1, 2 1, 3 1, 4 1, 5
2, 1 2, 2 2, 3 2, 4 2, 5
3, 1 3, 2 3, 3 3, 4 3, 5
4, 1 4, 2 4, 3 4, 4 4, 5
5, 1 5, 2 5, 3 5, 4 5, 5
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Figure 4: PEMY -specific effects on CD4 count. The plot in each cell represents estimates for the
effect with comparison-level treatment, e, equal to the first index of the cell and baseline-level
treatment, e′ equal to the second index of the cell. That is, comparison level treatment varies
across rows and baseline level treatment varies across columns. Within each plot, the dots and
vertical bars represent point estimates using the four estimators and their corresponding bootstrap
confidence intervals.
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